Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Radiopharmaceuticals × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Tumor-Agnostic 1 Thoracic 1 Genitourinary 1 Endocrine 1 Breast 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 55 lutetium Lu 177 dotatate 51 Magnetic Resonance Spectroscopy 33 Cisplatin 26 Temozolomide 25 pembrolizumab 24 gallium Ga 68 dotatate 22 Octreotide 22 lanreotide 21 Nivolumab 21 cabozantinib 18 3-Iodobenzylguanidine 18 Specimen Handling 17 Capecitabine 17 Etoposide 16 pasireotide 15 lenvatinib 15 Sunitinib 15 Paclitaxel 15 dabrafenib 14 Carboplatin 14 Bevacizumab 14 trametinib 13 surufatinib 13 Surgical Procedures, Operative 11 Ipilimumab 11 Injections 11 Doxorubicin 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sorafenib 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡